Suppr超能文献

血液透析患者静脉注射蔗糖铁的安全性。

Safety of intravenous injection of iron saccharate in haemodialysis patients.

作者信息

Sunder-Plassmann G, Hörl W H

机构信息

Department of Medicine, University of Vienna, Austria.

出版信息

Nephrol Dial Transplant. 1996 Sep;11(9):1797-802.

PMID:8918625
Abstract

BACKGROUND

The most frequent i.v. iron preparations used for haemodialysis patients are iron dextran, iron gluconate and iron saccharate. Possible side effects include anaphylactic reactions due to preformed antibodies to dextran or vascular reactions due to unbound iron during treatment with iron gluconate or iron saccharate.

METHODS

Four dosage regimens of i.v. iron saccharate therapy were studied: 10, 20, 40 and 100 mg, which were given over a time period of 1 min after the end of the dialysis session. Iron metabolism parameters (serum iron concentrations, transferrin saturation and serum ferritin levels) were measured at 0, 1, 5, 15 and 30 min after application and immediately prior to the next dialysis session. All 18 regular haemodialysis patients studied received recombinant human erythropoietin (rHuEpo).

RESULTS

Serum iron levels and transferrin saturation increased significantly following i.v. injection of all doses of iron saccharate. Iron 'oversaturation' of transferrin iron binding did not occur in patients with transferrin levels > 180 mg/dl. However, in patients with transferrin levels < 180 mg/dl the injection of 100 mg iron saccharate resulted in a transferrin saturation of 102.6 +/- 39.5% (two patients with transferrin levels of 87 and 92 mg/dl had transferrin saturation of 119.8 and 149.7%, two patients with transferrin levels of 148 and 171 mg/dl had transferrin saturations of 77.9 and 63.1%, respectively). Serum ferritin levels remained unchanged during the post-injection period and increased by the next dialysis session following injection of 100 mg iron saccharate by 165%.

CONCLUSION

It is concluded that intravenous iron saccharate injection (10-100 mg even within 1 min) does not result in 'oversaturation' of transferrin iron binding if serum transferrin levels are > 180 mg/dl (high-risk patients; transferrin < 100 mg/dl). This may explain, at least in part, the minimal side effects observed during the i.v. application of iron saccharate. Low-dose i.v. iron saccharate (10-40 mg) is recommended for iron supplementation of haemodialysis patients. If injection of 100 mg is necessary, serum transferrin level should exceed 180 mg/dl. There is, however, no need for fast i.v. injection during routine iron supplementation.

摘要

背景

用于血液透析患者的最常用静脉铁剂是右旋糖酐铁、葡萄糖酸铁和蔗糖铁。可能的副作用包括因对右旋糖酐预先形成抗体导致的过敏反应,或在使用葡萄糖酸铁或蔗糖铁治疗期间因未结合铁导致的血管反应。

方法

研究了四种静脉注射蔗糖铁疗法的给药方案:10mg、20mg、40mg和100mg,在透析 session 结束后1分钟内给药。在给药后0、1、5、15和30分钟以及下次透析 session 前立即测量铁代谢参数(血清铁浓度、转铁蛋白饱和度和血清铁蛋白水平)。所有18名接受研究的常规血液透析患者均接受重组人促红细胞生成素(rHuEpo)。

结果

静脉注射所有剂量的蔗糖铁后,血清铁水平和转铁蛋白饱和度显著升高。转铁蛋白水平>180mg/dl的患者未发生转铁蛋白铁结合的“过饱和”。然而,在转铁蛋白水平<180mg/dl的患者中,注射100mg蔗糖铁导致转铁蛋白饱和度为102.6±39.5%(两名转铁蛋白水平分别为87和92mg/dl的患者转铁蛋白饱和度为119.8和149.7%,两名转铁蛋白水平分别为148和171mg/dl的患者转铁蛋白饱和度分别为77.9和63.1%)。注射后血清铁蛋白水平在注射后期间保持不变,在注射100mg蔗糖铁后的下次透析 session 时升高了165%。

结论

得出结论,如果血清转铁蛋白水平>180mg/dl(高危患者;转铁蛋白<100mg/dl),静脉注射蔗糖铁(即使在1分钟内注射10 - 100mg)不会导致转铁蛋白铁结合的“过饱和”。这至少可以部分解释在静脉应用蔗糖铁期间观察到的最小副作用。建议使用低剂量静脉注射蔗糖铁(10 - 40mg)为血液透析患者补充铁。如果需要注射100mg,血清转铁蛋白水平应超过180mg/dl。然而,在常规补铁期间无需快速静脉注射。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验